The global gastroparesis management market size is expected to reach US$ 6,035.11 million by 2027 from US$ 4,348.61 million in 2021 at a CAGR of 4.6% from 2021 to 2027. Gastroparesis is also called as delayed gastric emptying, is a disorder of stomach that hinder the movement of food from stomach to small intestine. Generally, muscles of the GI tract controlled by the vagus nerve, that contract to move the food contents throughout the GI tract. Gastroparesis occurs when vagus nerve damaged by illness or the injury which leads to slower movement of food contents from the stomach to the small intestine. Majority of people with gastroparesis have idiopathic gastroparesis of which cause is unknown. Diabetes is commonly known the cause of gastroparesis. Elevated sugar levels in diabetics believed to cause damage of vagus nerve and other causes of gastroparesis include gastric surgery, Parkinson’s diseases, and multiple sclerosis. Gastroparesis generally found in females than males. The gastroparesis management market report evaluates all-inclusive data that enriches the scope, understanding and application of this report. Gastroparesis is a condition that primarily affects diabetics with type 1 and type 2 diabetes. The stomach takes an abnormally long time to empty its contents in this condition. Gastroparesis is treated with drugs such as erythromycin, antiemetics, and Reglan. Furthermore, due to the increased prevalence of type 1 and type 2 diabetes, which may increase the risk of gastroparesis, there are 119 completed and continuing clinical trials for gastroparesis medicines. This increases the demand for these drugs and, to some extent, fuels the total market. However, the market may be hampered by adverse effects associated with gastroparesis medications.